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ABSTRACT 
Acute myocardial infarction and subsequent heart failure are leading causes of death worldwide. Stem cell-based 
therapies have improved cardiac function in recent clinical trials, but cardiomyocyte regeneration has not been 
demonstrated in human hearts. Angiogenesis and restoration of cardiac perfusion have been successfully per-
formed using bone marrow derived stem cells and other adult stem cells. Resident cardiac stem cells are known 
to differentiate into multiple heart cell types, including cardiomyocytes. Furthermore, induced pluripotent stem 
cells are a focus of research due to the great potential for customized stem cell therapy. (Korean Circ J 2009;39:87-92) 
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Introduction 
 
The self-repair and renewal capacity of the human 
heart is known to be very limited.
1) After acute myo-
cardial infarction, the ischemic injury of the heart tissue 
is usually irreversible despite aggressive medical and re-
vascularization treatment.
2) Significant loss of functional 
myocardium usually progresses to irreversible cardiomyo-
pathy. Hence, acute myocardial infarction and subse-
quent heart failure remain challenging healthcare prob-
lems and leading causes of death worldwide. Stem cells 
have been continuously challenged to regenerate the in-
jured human heart. Now myocardium has become an 
attractive target of stem cell therapy with vessels, valves, 
and even conducting systems in the cardiovascular system. 
Although considerable research has been done, there 
has still been no definite advance in the practical human 
application of stem cell therapy. In this review, we discuss 
currently available cardiac progenitor cells and focus on 
recently identified promising progenitor cells for myo-
cardial repair. 
 
Contents 
 
Cardiac repair and cardiomyocytes   
It has long been accepted that cardiac muscle cells 
cannot divide. In 2001, Beltrami et al.
3) first found that 
mitotic figures are present around the ischemic bound-
ary of acute myocardial infarction. This observation in-
dicated that cardiac muscle cells could undertake cell 
division and repair ischemic damage spontaneously. 
Anversa et al.
4) showed further evidence of the human 
heart’s regenerative capacity. A male patient, who had 
been transplated with a heart of a female donor, died 
due to immune rejection. At his autopsy, many cardio-
myocytes and arterioles with Y-chromosomes were ob-
served in the female donor’s heart. This implies that the 
pluripotent cells migrated to the donor heart from the 
recipient’s remnant cardiac tissue or from an extra-car-
diac organ.   
These findings encouraged reconsideration of tradi-
tional beliefs concerning cardiac self-regeneration. It is 
now accepted that the human heart has some capacity 
to repair myocardial injury. However, the self-regenera-
tion ability of human heart is not naturally potent to 
influence clinical outcomes. In addition, it is still not 
known if the replicating cells are in-situ myocytes or 
migrant cells from other organs. The recruitment and 
potentiation of self-regenerative cardiomyocytes remain 
limiting steps for enhancing regeneration of damaged 
myocardium.  
 
Cardiac regeneration and stem cells   
Stem cells are progenitors of specialized cells that im-
part function to tissues or organs. Stem cells are pluri-
potent; they can expand, and they possess the potential 
to differentiate into other cellular lineages.
5) Hence, stem 
cells have become the most promising means of treat-
ment in regenerative cardiovascular medicine. The best 
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established source for adult stem cells is the bone mar-
row. Bone marrow cells appear to have the ability to re-
populate many non-hematopoietic tissues like myoblasts 
and endothelial cells.
6) 
Stem cells are usually classified according to the fol-
lowing conditions: origin (fetal or adult), type of organ 
or tissue from which the cells are derived, final differen-
tiation fate, and surface cell markers. The cells which 
are known to have cardiogenic potential, are listed in 
Table 1. The frequently used terms in stem cell biology 
are listed and defined in Table 2. The terminology is il-
lustrated to facilitate easy understanding (Fig. 1).  
The precise cellular and molecular events that generate 
pluripotency are largely undetermined. The intra-cellular 
processes are illustrated in Fig. 2, which shows the several 
steps that regulate pluripotency and differentiation. In 
stable cellular conditions, the regulating genes of OCT4, 
SOX2, and Nanog are inhibited by histone acetylation 
or deoxyribonucleic acid (DNA) methylation at the pro-
moter regions. Chemicals like 5-azacytidine and valproic 
acid activate these genes through DNA demethylation 
or inhibition of histone acetylation.
7) Moreover, the 
transcription factors of OCT4, SOX2, c-Myc, and KLF4 
directly generate induced pluripotent stem (iPS) cell 
Table 2. Terminology frequently used in stem cell biology
(A) Differentiation: a process by which a less specialized cell be-
comes a more specialized cell. This occurs during the develop-
ment of a multi-cellular organism. In adults, differentiation is
common during tissue repair and normal cell turnover. One
example of normal differentiation is hematopoiesis. 
(B) Dedifferentiation: a process by which a terminally differen-
tiated cell reverts to an earlier developmental stage as part of
a regenerative process. During culture, cells undertake dedif-
ferentiation while they lose properties they originally had and
change shapes. As an aberrant part of the cell cycle, dediffe-
rentiation facilitates cancer formation.  
(C) Transdifferentiation: the irreversible switching of one differ-
entiated cell to another type. Transdifferentiation is a type of 
metaplasia of adult cells, including the inter-conversion of stem
cells. 
(D) Pluripotent stem cell: cells have the ability of self-renewal 
through mitotic division, and they differentiate into a diverse
range of specialized cell types from all three germ layers. In
contrast to pluripotent stem cells, progenitor cells are capable
of differentiating into a limited number of tissue types. 
(E) Multiple stem cells: co-existence of multiple stem cells with
different differentiation fates.  
(F) Cell fusion: an important cellular process that occurs during
differentiation of muscle, bone, and trophoblast cells during
embryogenesis and morphogenesis. Cell fusion is a necessary
event in the maturation of cells so they maintain their specific
function throughout growth. 
(G) Proliferation: an increase in the number of differentiated or
undifferentiated cells due to cellular division in vivo or in cul-
ture. 
(H) Cell growth: an increase in cellular volume. At a certain degree,
cell growth gives rise to cell division.  
Table 1. Various stem cells that carry the potential for of cardio-
myocyte differentiation 
  Bone marrow  Endothelial progenitor cell (EPC) 
Bone marrow mononuclear stem cell
(BMMNC)  Adult 
stem cells 
 
Mesenchymal stem cell (MSC) 
  Peripheral blood  Hematopoietic stem cell (HSC) 
 
Heart 
 
 
Adult cardiac stem cells (isl1
+,  
c-Kit
+Lin-, Sca
+c-Kit-,  
cardiosphere, SP cells) 
  Skeletal muscle  Skeletal myoblast   
  Blastocyst  Embryonic stem (ES) cell 
  Induced pluripotent stem (iPS) cell  Embryonic 
stem cells  Fetal heart  Fetal cardiac cell 
   Fetal  epicardial  cell   
SP cells: side population cells 
 
② Receptors 
① Cytokines  ⑦ Proteins 
⑥ mRNA 
⑤ DNA 
④ Transcription 
factors 
③ Internal  signial 
molecules 
Fig. 2. Schematic diagram of intra-cellular transduction system 
for pluripotency. The generation of stem cell pluripotency is under
genetic regulation. There are several intra-cellular steps occurring
between receptor-binding and final protein expression. In labo-
ratory experiments, each step can be modified for a stem cell’s 
pleuripotency. DNA: deoxyribonucleic acid,  mRNA: mesenger 
ribonucleic acid. 
(A) 
Differentiation 
(B) 
Dedifferentiation 
(C) 
 Transdifferentiation 
(D) Pluripotent   
stem cell 
(E) Multiple 
stem cells 
(F)  
Cell fusion 
(G)  
Cell proliferation 
(H)  
Cell growth 
Fig. 1. Schematic diagrams of regeneration and renewal poten-
tial of stem cells.  
 
Ki Hyun Byun, et al.·89 
formation.
3) As an example of the modulation of inter-
nal signal transduction molecules, inhibition of bone 
morphogenetic protein (BMP) induces cardiomyocyte 
differentiation.
8) The known methods to control pluri-
potency include modulation of extra-cellular growth 
factors, cytokines, internal signal transduction molecules, 
and micro ribonucleic acid (microRNA). However, the 
mechanisms of proliferation and differentiation should 
be further elucidated. Understanding the biological be-
havior of stem cells may speed up stem cell therapy.   
 
Embryonic stem cells 
Embryonic stem (ES) cells have all the requirements 
of a stem cell: clonality, self-renewal, and multipoten-
tiality. ES cells can completely differentiate into cardio-
myocytes or any other type of cell in the human body.
9) 
However, ethical debates have been an obstacle in human 
application of these cells, because derivation of human 
ES cells requires destruction of human embryos. Fur-
thermore, ES cells carry the risk of teratoma formation 
and immune rejection, which disturb transplanted cell 
function in the recipient body.
9) Hence, autologous adult 
stem cells have attracted attention for cardiovascular ther-
apy. They are free from the risks of teratoma formation 
and immune rejection, as well as the ethical problems 
associated with ES cell research.   
 
Bone marrow derived stem cells   
Stem cells were once believed to differentiate into the 
cells of the tissue from which they derived. However, 
transdifferentiation introduced the concept that adult 
tissue-specific stem cells could differentiate into other 
lineages. The bone marrow is regarded as a central re-
pository of primitive stem cells that can repopulate so-
matic tissues. Endothelial progenitor cells (EPCs), bone 
marrow derived mononuclear cells (BMMNCs), and 
mesenchymal stem cells (MSCs) are well known the sub-
populations of bone marrow derived stem cells that 
have pooled data associated with human cardiovascular 
disease. 
Orlic et al.
10) reported that bone marrow derived stem 
cells regenerate infarcted myocardium. Human bone 
marrow derived stem cells have been used in clinical 
trials during the last decade. Some achievements have 
been made in human acute myocardial infarction and 
ischemic cardiomyopathy. The representative human 
clinical trials are summarized
2) in Table 3. All of the 
studies have shown that human bone marrow derived 
stem cells are safe for intra-coronary delivery or direct 
intramyocardial injection.
1) Bone marrow derived mo-
nonuclear cells, mesenchymal stem cells, and circulat-
ing endothelial progenitor cells have been extensively 
studied.
11) 
Bone marrow derived stem cells have been shown to 
promote short-term increases in ejection fraction in the 
range of 2% to 5% in early non-randomized pilot stud-
ies. Post-infarction remodeling was prevented and myo-
cardial perfusion was restored in human trials.
11)12) How-
Table 3. Clinical trials of stem cell therapy in human cardiovascular diseases
Disease  Trial  Study design  N  Cells  Delivery method  Results  Adverse effects 
MAGIC RCT  097 Skeletal myoblast  Epicardial+CABG  Early terminated with   
no effect 
No increase of VT 
Erbs et al.  RCT  026 CPC 
Intracoronary+ 
CTO  
recanalization 
Improved EF, perfusion 
reduced infarction size 
None reported 
Hendrikx et al.  RCT  020 BMMNC  Epicardial+CABG    
TOPCARE- 
CHD 
3 phase  075 BMMNC vs. 
CPC 
Intracoronary  Improved EF, regional 
contractility 
3 coronary dissection 
1 VF 
Ischemic 
cardiomyopathy 
FOCUS   030 BMMNC  Transendocardial  Ongoing  
TOPCARE Randomized  059 BMMNC vs. 
c-EPC 
Intracoronary  Improved EF, perfusion 
reduced infarction size 
None reported 
Chen et al.  RCT  069 MSC  Intracoronary  Improved EF, viability  None reported 
BOOST RCT  060 BMMNC  Intracoronary 
Transient improve EF, 
improved diastolic   
function 
None reported 
REVIVAL-2 RCT  114  G-CSF mobilized 
PBSC 
Intracoronary  No effect on EF or 
infarction size 
G-CSF related muscle 
discomfort 
MAGIC cell- 
3-DES 
RCT  096 G-CSF mobilized 
PBSC 
Intracoronary Improved  EF  DES prevented   
restenosis 
ASTRAMI RCT  100  BMMNC  Intracoronary No effect on EF or 
infarction size 
None reported 
Acute myocardial 
infarction 
REPAIR-AMI RCT  204  BMMNC  Intracoronary  Improved  EF  None  reported 
BMMNC: bone marrow mononuclear cell, DES: drug eluting stent, RCT: randomized clinical trial, c-EPC: circulating endothelial pro-
genitor cell, MSC: mesenchymal stem cell, PBSC: peripheral bone marrow stem cell, EF: ejection fraction, CPC: circulating progenitor 
cell, CABG: coronary artery bypass surgery, CTO: chronic total occlusion, G-CSF: granulocyte colony-stimulating factor, VT: ventricular 
tachycardia, VF: ventricular fibrillation  
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ever, larger randomized studies failed to show consis-
tent results, especially in long-term follow-up. In addi-
tion, the improvement in ejection fraction was too small 
to expect that the injected cells were successfully en-
grafted and contracted synchronously with resident cells. 
Improvements in post-infarction remodeling and exercise 
tolerance were superior to those obtained in ejection 
fraction.
13-15) 
Murry et al.
16) reported that bone marrow derived 
stem cells do not transdifferentiate into cardiomyocytes 
in a myocardial infarction animal model. According to 
the report of Balsam et al.
17), the beneficial short-term 
effects are mostly due to secreted factors (paracrine ef-
fect), not to functional engraftment of bone marrow 
derived stem cells. This paracrine theory is now gen-
erally accepted, and new vessel formation and anti-
apoptosis are regarded as other mechanisms contribut-
ing to functional cardiac improvement.
2) 
Consensus dictates that functional improvement de-
pends on the salvage of ischemic, jeopardized myocar-
dium. However, fusion of implanted cells with host car-
diomyocytes is observed with lower frequency.
18) A sub-
analysis of the clinical trials indicated that patients with 
larger or more severe infarctions derive more benefits 
from stem cell therapy.
19) A meta-analysis of pooled data 
reported that improvements in heart function are sig-
nificant.
20) The long-term follow-up data are expected 
to provide us more information about therapeutic ef-
ficacy. 
 
Endogenous cardiac stem cells 
Endogenous cardiac stem cells (CSCs) do not carry 
the risk of immune ejection or teratoma formation and 
are free from the ethical debates associated with the use 
of ES cells. Cardiac originated progenitor cells are also 
much more easily accessed for clinical trials and thera-
peutic applications compared to other types of progeni-
tor cells.   
Messina et al.
21) identified a clonal cluster called car-
diospheres in a suspension culture of a human myo-
cardial tissue biopsy. These cardiospheres consisted of 
c-Kit
+ cells and gave rise to cardiomyocytes, vascular 
smooth muscles, and endothelial cells when transplant-
ed into an immunodeficient mouse.
22) Another cardiac 
progenitor cell was isolated by the binding affinity to 
anti-mouse Sca-1 antibody from a human adult heart 
biopsy. These were called Sca-1
+ cells. However, there is 
debate concerning their cardiac progenicity because these 
cells require 5-azacytidine demethylation and cardiac fi-
broblasts to differentiate into cardiomyocytes.
23)  
Recently, as another progenitor cell source, an endog-
enous epithelial population has been identified in hu-
man epicardium.
24) These cells are effective at promoting 
a short-term increase in ejection fraction in a mouse 
model. The epicardium may be a novel source of cardiac 
progenitor cells in human heart. Some reports have 
shown an association between Isl-1
+ cardiac progenitor 
cells and the epicardium.
25) As an animal with epicardial 
regeneration capacity, the zebrafish is famous for exhi-
biting spontaneous cardiac regeneration. When the car-
diac apex is removed, the pericardial cells are activated, 
and they replace the lost myocardium by retroprogram-
ming genes to a pluripotent state.
26) 
To look for optimal endogenous cardiac progenitor 
cells, researchers are working with human adult heart 
tissues. However, a definite marker of CSCs has not yet 
been identified, although c-Kit, Sca-1, and Isl1 are 
known.
27) Furthermore, it remains to be determined if 
CSCs originate in the heart or are derived from another 
tissue. 
 
Induced pluripotent stem cells 
Recently, iPS cells were derived by direct retropro-
gramming adult endogenous fibroblasts to a pluripotent 
state.
7) In 2006, Takahashi et al.
28) reported for the first 
time that over-expression of four transcription factors 
(OCT4, SOX2, c-Myc, and KLF4) caused mouse adult 
fibroblasts to convert into pluripotent stem cells. One 
year later, Yu
29) succeeded in generating human iPS cells 
from adult skin fibroblasts. 
iPS cells show the same characteristics of ES cells in 
terms of cell surface markers and gene expression. Fur-
thermore, they can differentiate into cells of all three 
embryonic germ layers.
30) Moreover, iPS cells are not as-
sociated with an immune rejection or ethical difficulties. 
Despite survival and safety remain to be addressed, the 
development of iPS cells presents new and exciting 
prospects in cell-based therapy for cardiac disease. 
 
Future directions   
Knowledge of stem cell biology will help advance the 
therapeutic application of stem cells. Such knowledge 
can be achieved through the coordinated progress of 
network activities of laboratory stem cell research, te-
chnological development, and clinical research. More 
information will help us determine the most appropriate 
cell type, cell fate, mechanism of effect, cell modifica-
tions, and feasible delivery methods.   
The main fields of stem cell research can be divided 
into cell isolation, manipulation, and survival enhance-
ment, as shown in the schematic flow-chart of stem cell 
therapy (Fig. 3). Technical development is being pursu-
ed to improve delivery systems, tissue engineering, quality 
assurance, and commercially available cell processing 
systems. In order for the novel concept of stem cell 
therapy to be realized, well-regulated, ethically proven, 
randomized clinical trials are needed to obtain back-
ground on the therapeutic mechanisms. The balance 
between safety and efficacy is the first priority for stem 
cell therapy to be approved clinically in human disease.  
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